Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1
(PD-1) are inhibitory checkpoints that are commonly seen on activated T cells and have …

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, yielding
significant antitumor responses across multiple cancer types. Combination ICI therapy with …

The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …

Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T
lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or PD-1 ligand …

Preclinical data suggest that combining a checkpoint inhibition with immunomodulatory
derivative can increase anticancer response. We designed a dose-escalation study using a …

Checkpoint receptor blockers, known to act by blocking the pathways that inhibit immune
cell activation and stimulate immune responses against tumor cells, have been immensely …

Purpose The aim of this study was to evaluate the risk of immune-related adverse events
(irAEs) among cancer patients receiving nivolumab-plus-ipilimumab therapy and nivolumab …

Background Combination therapy with immune checkpoint inhibitors (ICIs) has been applied
in the clinic to achieve synergistic effects and to improve clinical efficacy. Compared with …

Objective: To provide the clinician with an update and the current status and future direction
of approved immune checkpoint inhibitors (ICIs) in oncology. Data Sources: A PubMed …

Over the past few decades, different inhibitory receptors have been identified, which have
played prominent roles in reducing anti-tumor immune responses. The role of immune …